SNAP-8: Scientific Profile

Publicado el 12 de julio de 2026

SNAP-8 (Acetyl Octapeptide-3, CAS 868844-74-0) is an acetylated octapeptide related to Acetyl Hexapeptide-8 (Argireline), studied in cosmetic research for its ability to interfere with the SNARE complex and attenuate neurotransmitter exocytosis in topical models. Its proposed mechanism reduces acetylcholine-mediated muscle contraction, which has positioned it as an object of study in the attenuation of expression lines. Research-use material.

SNAP-8, whose INCI name is Acetyl Octapeptide-3 (also described as Acetyl Glutamyl Heptapeptide-1), is a synthetic octapeptide acetylated at its N-terminal end with a molecular mass close to 1075 g/mol and CAS number 868844-74-0. It belongs to the family of so-called "myorelaxant peptides" or those with a topical neuromodulator-type action, a group of cosmetic peptides designed to mimic fragments of proteins involved in neurotransmitter release. It should be noted from the outset, for the sake of evidentiary honesty, that although this catalog classifies it within a broad category, SNAP-8 is not a nootropic in the classical sense: its documented body of research corresponds almost entirely to the dermocosmetic field and to in vitro models of exocytosis, not to models of cognition.

SNAP-8 is a structural extension of Acetyl Hexapeptide-8 (commercially known as Argireline), with which it shares the peptide core. Both peptides reproduce a sequence derived from the amino-terminal end of the SNAP-25 protein (Synaptosomal-Associated Protein of 25 kDa), an essential component of the SNARE complex. SNAP-8 extends that fragment by two additional residues, which in the industry literature has been associated with a theoretically greater competitive affinity for the assembly of the complex. As a precaution, the exact amino acid sequence is not stated here in a closed form, since public sources present variations in the notation of the C-terminal end; only the kinship relationship with the EEMQRR hexapeptide of Argireline and the acetylated nature of the N-terminal end are documented with confidence.

The proposed mechanistic basis centers on the SNARE complex, the protein machinery that mediates the docking and fusion of synaptic vesicles with the presynaptic membrane to release their content, including acetylcholine and catecholamines. The ternary SNARE complex is formed from SNAP-25, syntaxin, and VAMP/synaptobrevin. The working hypothesis, originally posited by the manufacturer of the ingredient, is that SNAP-8, by mimicking the N-terminal segment of SNAP-25, competes with the native protein for its incorporation into the complex. This competition would destabilize the assembly of the SNARE complex, reducing its efficiency and, consequently, diminishing the calcium-dependent exocytosis of neurotransmitters at the neuromuscular junction. In functional terms, a lower release of acetylcholine would translate into a relaxation of the contraction of the muscle fibers, which is why these peptides have been colloquially termed "botulinum-toxin-type topical alternatives", although the analogy is imperfect: botulinum toxin proteolytically cleaves SNAP-25, whereas SNAP-8 would act by reversible and non-enzymatic competition, with a potency several orders of magnitude lower and a cutaneous penetration limited by its hydrophilic peptidic character.

The documented research applications are concentrated on three fronts. The first is the study of skin aging and expression lines: in topical formulations, SNAP-8 has been investigated as an agent to attenuate the depth of dynamic wrinkles associated with repeated muscle contraction, generally in direct comparison with Argireline. The second is the in vitro study of the exocytosis mechanism itself, using SNAP-8 as a probe of the dynamics of the SNARE complex and of catecholamine release in cell models. The third is galenic and delivery research, since the skin barrier represents a substantial obstacle to the penetration of a peptide of this size; much of the applied work has revolved around delivery systems, encapsulation, and permeation enhancers that make it possible to reach effective concentrations in the dermis.

As for the level of evidence, it is important to be transparent. Most of the data supporting the efficacy of SNAP-8 comes from cosmetic-industry studies and trials with small panels, frequently without robust independent control, blinding, or replication by external groups. There is no body of large-scale, peer-reviewed randomized clinical trials supporting therapeutic claims, and its recognized use is exclusively that of a topical cosmetic ingredient, not that of a drug. The topical bioavailability of the peptide is a critical and controversial point: given its molecular weight and its hydrophilicity, its capacity to cross the intact stratum corneum without adequate delivery systems has been questioned in the literature. For this reason, any interpretation of its effects in models should be considered preliminary and dependent on the specific formulation used.

For the researcher, SNAP-8 is of interest precisely as a tool to interrogate the relationship between modulation of the SNARE complex, neurotransmitter exocytosis, and the cutaneous manifestations of muscle contraction, as well as for comparative structure-activity studies against other peptides derived from SNAP-25. Its experimental value lies in offering an extended-sequence variant against which to test hypotheses of affinity and penetration. All the material described is intended exclusively for laboratory research and characterization use.